Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Alterity Therapeutics Limited is a biotechnology business based in the US. Alterity Therapeutics shares (ATHE) are listed on the NASDAQ and all prices are listed in US Dollars. Alterity Therapeutics employs 12 staff and has a trailing 12-month revenue of around USD0.00.
|52-week range||USD$0.55 - USD$2.96|
|50-day moving average||USD$1.52|
|200-day moving average||USD$1.64|
|Wall St. target price||USD$4.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.63|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$-352,922|
|Return on assets TTM||-38.31%|
|Return on equity TTM||-71.91%|
|Market capitalisation||USD$51.6 million|
TTM: trailing 12 months
There are currently 169,231 Alterity Therapeutics shares held short by investors – that's known as Alterity Therapeutics's "short interest". This figure is 18% up from 143,387 last month.
There are a few different ways that this level of interest in shorting Alterity Therapeutics shares can be evaluated.
Alterity Therapeutics's "short interest ratio" (SIR) is the quantity of Alterity Therapeutics shares currently shorted divided by the average quantity of Alterity Therapeutics shares traded daily (recently around 313390.74074074). Alterity Therapeutics's SIR currently stands at 0.54. In other words for every 100,000 Alterity Therapeutics shares traded daily on the market, roughly 540 shares are currently held short.
However Alterity Therapeutics's short interest can also be evaluated against the total number of Alterity Therapeutics shares, or, against the total number of tradable Alterity Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Alterity Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Alterity Therapeutics shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Alterity Therapeutics shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Alterity Therapeutics.
Find out more about how you can short Alterity Therapeutics stock.
We're not expecting Alterity Therapeutics to pay a dividend over the next 12 months.
Alterity Therapeutics's shares were split on a 1:6 basis on 23 March 2016. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Alterity Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Alterity Therapeutics shares which in turn could have impacted Alterity Therapeutics's share price.
Over the last 12 months, Alterity Therapeutics's shares have ranged in value from as little as $0.55 up to $2.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Alterity Therapeutics's is 1.0371. This would suggest that Alterity Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia. .
Steps to owning and managing TREB-U, with 24-hour and historical pricing before you buy.
Steps to owning and managing TIG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDAC, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB, with 24-hour and historical pricing before you buy.
Steps to owning and managing TREB-WS, with 24-hour and historical pricing before you buy.
Steps to owning and managing TDG, with 24-hour and historical pricing before you buy.
Steps to owning and managing TACT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TT, with 24-hour and historical pricing before you buy.
Steps to owning and managing TROX, with 24-hour and historical pricing before you buy.
Steps to owning and managing TRVG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.